Suppr超能文献

阳性淋巴结及放射性碘治疗对N1b型乳头状甲状腺癌患者生存的影响

Impact of positive lymph nodes and RAI therapy on survival in N1b papillary thyroid carcinoma.

作者信息

Jian Jie, Wei Meng, Li Xumei, Xiong Qian, Xiang Jiangming, Zhao Shengping, Peng Yuxi, Huang Jingjing

机构信息

Department of Pathology, Chongqing Changshou District Maternal and Child Health Hospital, Chongqing, China.

Department of Surgery, Chongqing Changshou District Maternal and Child Health Hospital, Chongqing, China.

出版信息

Front Endocrinol (Lausanne). 2025 May 22;16:1551075. doi: 10.3389/fendo.2025.1551075. eCollection 2025.

Abstract

BACKGROUND

Patients with N1b papillary thyroid carcinoma (PTC) was associated with a worse prognosis. The prognostic role of positive lymph nodes (PLN) and whether postoperative radioactive iodine (RAI) therapy conferred a survival benefit were debatable issues in these patients.

METHODS

Data were drawn from the SEER database for PTC patients with clinical N1b disease diagnosed between 2004-2015. All patient underwent total thyroidectomy with or without RAI. Patients were categorized by age (≥55 years and <55 years) and analyzed based on PLN. Propensity score matching (PSM) were used to balance characteristics between patients who did and did not receive RAI therapy. Overall survival (OS) was the primary outcome. Kaplan-Meier survival analysis and Cox analysis were performed.

RESULTS

A total of 4343 N1b PTC patients were included, with 884 patients aged ≥55 years and 3459 patients aged <55 years. In patients aged ≥55 years, the optimal PLN cutoff for risk stratification was 8. Those with PLN ≥9 had significantly lower 5-year (83.7% vs. 90.1%), 10-year (67.4% vs. 78.8%) and 15-year (50.3% vs. 59.5%) OS rates. After adjusting, the hazard ratio for death in the PLN ≥9 group increased by 30%. After PSM, in subgroup of aged ≥55 years and PLN ≥9, the survival benefit was notable in those received RAI therapy. In contrast, for patients aged ≥55 years and PLN ≤8 or aged <55 years, no survival difference was found between those received RAI and those not.

CONCLUSIONS

In N1b PTC patients aged ≥55 years, PLN ≥9 predicted a poorer survival. Postoperative RAI therapy offered survival benefits for this subgroup.

摘要

背景

N1b 期甲状腺乳头状癌(PTC)患者预后较差。阳性淋巴结(PLN)的预后作用以及术后放射性碘(RAI)治疗是否能带来生存获益,在这些患者中仍是有争议的问题。

方法

数据来源于监测、流行病学和最终结果(SEER)数据库,纳入2004年至2015年期间诊断为临床N1b期疾病的PTC患者。所有患者均接受了全甲状腺切除术,部分患者接受了RAI治疗。患者按年龄(≥55岁和<55岁)分类,并根据PLN进行分析。采用倾向评分匹配(PSM)来平衡接受和未接受RAI治疗患者的特征。总生存期(OS)是主要结局指标。进行了Kaplan-Meier生存分析和Cox分析。

结果

共纳入4343例N1b期PTC患者,其中884例年龄≥55岁,3459例年龄<55岁。在年龄≥55岁的患者中,风险分层的最佳PLN截断值为8。PLN≥9的患者5年(83.7%对90.1%)、10年(67.4%对78.8%)和15年(50.3%对59.5%)总生存率显著较低。调整后,PLN≥9组的死亡风险比增加了30%。PSM后,在年龄≥55岁且PLN≥9的亚组中,接受RAI治疗的患者生存获益显著。相比之下,对于年龄≥55岁且PLN≤8或年龄<55岁的患者,接受RAI治疗和未接受RAI治疗的患者之间未发现生存差异。

结论

在年龄≥55岁的N1b期PTC患者中,PLN≥9预示着较差的生存率。术后RAI治疗为该亚组患者带来了生存获益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0024/12137069/57b0eab024b2/fendo-16-1551075-g001.jpg

相似文献

1
Impact of positive lymph nodes and RAI therapy on survival in N1b papillary thyroid carcinoma.
Front Endocrinol (Lausanne). 2025 May 22;16:1551075. doi: 10.3389/fendo.2025.1551075. eCollection 2025.
2
The Impact of Radioactive Iodine on Disease-Specific Survival in Low-to-Intermediate Risk N1b Papillary Thyroid Carcinoma.
Ann Surg Oncol. 2025 Mar;32(3):1698-1708. doi: 10.1245/s10434-024-16388-1. Epub 2024 Nov 6.
4
Efficacy of postoperative radioactive iodine therapy for patients with low and intermediate risk papillary thyroid carcinoma.
Endocrine. 2025 Feb;87(2):685-696. doi: 10.1007/s12020-024-04046-1. Epub 2024 Sep 23.
5
Decoding lymph node skip metastasis: impact on long-term outcomes in stage T1 papillary thyroid carcinoma.
Eur J Endocrinol. 2025 Mar 3;192(3):318-326. doi: 10.1093/ejendo/lvaf050.
6
Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
Front Endocrinol (Lausanne). 2022 Aug 11;13:960682. doi: 10.3389/fendo.2022.960682. eCollection 2022.
7
Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
Oral Oncol. 2018 Dec;87:152-157. doi: 10.1016/j.oraloncology.2018.10.041. Epub 2018 Nov 8.
8
UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Endocr Pract. 2019 Dec;25(12):1286-1294. doi: 10.4158/EP-2019-0155. Epub 2019 Aug 14.
9
Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Auris Nasus Larynx. 2021 Feb;48(1):148-153. doi: 10.1016/j.anl.2020.07.005. Epub 2020 Jul 25.
10
TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
Endocr Pract. 2016 Jul;22(7):822-31. doi: 10.4158/EP151088.OR. Epub 2016 Mar 28.

本文引用的文献

1
The Impact of Radioactive Iodine on Disease-Specific Survival in Low-to-Intermediate Risk N1b Papillary Thyroid Carcinoma.
Ann Surg Oncol. 2025 Mar;32(3):1698-1708. doi: 10.1245/s10434-024-16388-1. Epub 2024 Nov 6.
2
Long-term efficacy of lobectomy for stage T1 papillary thyroid carcinoma with varying degrees of lymph node metastasis.
Front Endocrinol (Lausanne). 2024 Aug 8;15:1453601. doi: 10.3389/fendo.2024.1453601. eCollection 2024.
4
American Thyroid Association Guidelines and National Trends in Management of Papillary Thyroid Carcinoma.
JAMA Otolaryngol Head Neck Surg. 2022 Dec 1;148(12):1156-1163. doi: 10.1001/jamaoto.2022.3360.
5
Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
Front Endocrinol (Lausanne). 2022 Aug 11;13:960682. doi: 10.3389/fendo.2022.960682. eCollection 2022.
6
Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma.
Cancers (Basel). 2022 Jul 28;14(15):3677. doi: 10.3390/cancers14153677.
8
Thyroid Lobectomy for T1 Papillary Thyroid Carcinoma in Pediatric Patients.
JAMA Otolaryngol Head Neck Surg. 2021 Nov 1;147(11):943-950. doi: 10.1001/jamaoto.2021.2359.
9
The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and Mutation.
Onco Targets Ther. 2021 Jun 29;14:3959-3969. doi: 10.2147/OTT.S308910. eCollection 2021.
10
The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer.
PLoS One. 2020 Jun 15;15(6):e0234843. doi: 10.1371/journal.pone.0234843. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验